Lilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bnLilly buys AtaiBeckley·$3.8bnOtsuka buys Transcend·$1.2bnAbbVie buys Gilgamesh·$1.2bnatai buys Beckley Psytech·terms undisclosedAbbVie takes an option on Gilgamesh·$2bn
Next issueIssue 16 · Tue 29 Sep 

Companies

Compass Pathways

Compass Pathways plc

HQ
United Kingdom
Registry
Companies House · 12696098
Status
active
Listing
Listed · CMPS
Current stage
clinical-stage; rolling NDA with FDA, final submission guided Q4 2026
Key people
Kabir Nath (CEO); Guy Goodwin (Chief Medical Officer)

find-and-update.company-information.service.gov.ukregistryverified 2026-09-15

Notes on the record

Headquartered in London with a US office in New York. Source of record for filings is Compass Pathfinder Limited on press releases. Holds UK ILAP designation for TRD. No marketing authorisation application disclosed to EMA or MHRA as of the Q1 2026 Form 10-Q; runs CTIS-authorised trials in nine EU/EEA states, which is a clinical trial authorisation and not a marketing application. Supersedes the row verified 2026-08-25. Companies House 12696098 (COMPASS Pathways plc, previous name Compass Rx Limited, incorporated 2020-06-24, active); operating subsidiary Compass Pathfinder Limited 10229259 (previous names Compass Pathways Limited, Compass Pathways Technologies Limited); Compass Pathfinder Holdings Limited 10830790. SEC EDGAR CIK 1816590: zero filings between 2026-09-08 and 2026-09-15 (submissions API HTTP 200). Companies House: no filing on or after 2026-09-08; latest are SH01 statements of capital filed 2026-09-01 and 2026-09-03 for allotments of 17 to 28 August 2026.

Assets

  • COMP360

    Phase 3 complete (COMP005, COMP006); rolling NDA, final submission guided Q4 2026 · treatment-resistant depression; PTSD programme separate

    euclinicaltrials.euregistryverified 2026-08-25

Registered trials

  • NCT05624268ClinicalTrials.gov

    PHASE3 · Treatment Resistant Depression · COMPLETED · United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • NCT05711940ClinicalTrials.gov

    PHASE3 · Treatment Resistant Depression · ACTIVE_NOT_RECRUITING · Canada, Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden, United Kingdom, United States

    clinicaltrials.govctgov registryverified 2026-08-31

  • 2023-505268-12-00CTIS

    Therapeutic confirmatory (Phase III) · Treatment-resistant depression · Authorised · Czechia, Denmark, France, Germany, Ireland, Netherlands, Poland, Spain, Sweden

    euclinicaltrials.euctis registryverified 2026-08-31

Deals

This company is not a party to any row in data/deals.csv.

In the briefing

9 issues tagged COMPASS.